Jasper Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Jasper Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for July 31, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.
NASDAQ
Jasper Therapeutics will hold its annual stockholders meeting virtually on July 3, 2025, to vote on director elections, auditor ratification, and executive compensation.
NASDAQ
Jasper Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 3, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.
NASDAQ
Jasper Therapeutics released a supplement to its proxy statement to correct an error regarding the treatment of abstentions on Proposals 3 and 4 for the upcoming Annual Meeting of Stockholders.
NASDAQ
Jasper Therapeutics will hold its annual stockholders meeting virtually on June 6, 2024, to vote on the election of directors, ratification of the accounting firm, and approval of equity incentive and employee stock purchase plans.
NASDAQ
Jasper Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, ratification of the accounting firm, and approval of equity incentive and employee stock purchase plans.